Novel |
PKD1 |
polycystin 1, transient receptor potential channel interacting |
- VxPx cargo-targeting to cilium
- VxPx cargo-targeting to cilium
|
|
- Polycystic kidney disease
|
Novel |
PKM |
pyruvate kinase M1/2 |
- Neutrophil degranulation
- Negative Regulation of CDH1 Gene Transcription
|
- Pyruvic acid
- L-Phospholactate
- 2-Phosphoglycolic Acid
- 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
- 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine
- 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
- Indoprofen
- Copper
- Polydatin
- Artenimol
|
|
Novel |
PKP2 |
plakophilin 2 |
- Keratinization
- Formation of the cornified envelope
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
Novel |
PLK1 |
polo like kinase 1 |
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Polo-like kinase mediated events
- Golgi Cisternae Pericentriolar Stack Reorganization
- Golgi Cisternae Pericentriolar Stack Reorganization
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Phosphorylation of the APC/C
- Phosphorylation of Emi1
- Condensation of Prophase Chromosomes
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Regulation of PLK1 Activity at G2/M Transition
- Activation of NIMA Kinases NEK9, NEK6, NEK7
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- RHO GTPases Activate Formins
- Mitotic Prometaphase
- Mitotic Metaphase/Anaphase Transition
- Mitotic Telophase/Cytokinesis
- Cyclin A/B1/B2 associated events during G2/M transition
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- EML4 and NUDC in mitotic spindle formation
- Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
|
- 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
- 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
- 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
- Wortmannin
- Fostamatinib
- Volasertib
|
|
Novel |
PPM1A |
protein phosphatase, Mg2+/Mn2+ dependent 1A |
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Energy dependent regulation of mTOR by LKB1-AMPK
|
|
|
Novel |
PRKCG |
protein kinase C gamma |
- Calmodulin induced events
- Disinhibition of SNARE formation
- Trafficking of GluR2-containing AMPA receptors
- G alpha (z) signalling events
- WNT5A-dependent internalization of FZD4
- Response to elevated platelet cytosolic Ca2+
|
- Tamoxifen
- Staurosporine
- Dequalinium
- Benzoyl peroxide
- Fostamatinib
|
- Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
|
Novel |
PSEN1 |
presenilin 1 |
- Nuclear signaling by ERBB4
- Degradation of the extracellular matrix
- Regulated proteolysis of p75NTR
- NRIF signals cell death from the nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- EPH-ephrin mediated repulsion of cells
- Neutrophil degranulation
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Noncanonical activation of NOTCH3
- TGFBR3 PTM regulation
|
|
- Alzheimer's disease (AD)
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Acne inversa; Hidradenitis supprativa
|
Novel |
PSEN2 |
presenilin 2 |
- Nuclear signaling by ERBB4
- Regulated proteolysis of p75NTR
- NRIF signals cell death from the nucleus
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- EPH-ephrin mediated repulsion of cells
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- NOTCH4 Activation and Transmission of Signal to the Nucleus
- Noncanonical activation of NOTCH3
- TGFBR3 PTM regulation
|
|
|
Novel |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
- Synthesis of 15-eicosatetraenoic acid derivatives
- Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- Biosynthesis of DHA-derived SPMs
- Biosynthesis of EPA-derived SPMs
- Biosynthesis of DPAn-3 SPMs
- Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives
|
- Dihomo-gamma-linolenic acid
- Icosapent
- Aminosalicylic acid
- Mesalazine
- Acetaminophen
- Indomethacin
- Indomethacin
- Nabumetone
- Ketorolac
- Tenoxicam
- Lenalidomide
- Celecoxib
- Tolmetin
- Rofecoxib
- Piroxicam
- Fenoprofen
- Valdecoxib
- Diclofenac
- Sulindac
- Flurbiprofen
- Etodolac
- Mefenamic acid
- Naproxen
- Sulfasalazine
- Phenylbutazone
- Meloxicam
- Carprofen
- Diflunisal
- Suprofen
- Salicylic acid
- Meclofenamic acid
- Acetylsalicylic acid
- Bromfenac
- Oxaprozin
- Ketoprofen
- Balsalazide
- Ibuprofen
- Lumiracoxib
- Magnesium salicylate
- Salsalate
- Choline magnesium trisalicylate
- Ginseng
- Antrafenine
- Antipyrine
- Tiaprofenic acid
- Etoricoxib
- Flufenamic acid
- Resveratrol
- 1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole
- Prostaglandin G2
- Niflumic acid
- Licofelone
- Nimesulide
- Cimicoxib
- Lornoxicam
- Aceclofenac
- Nepafenac
- Parecoxib
- Pomalidomide
- Cannabidiol
- Loxoprofen
- Dexibuprofen
- Dexketoprofen
- Droxicam
- Tolfenamic acid
- Firocoxib
- Morniflumate
- Propacetamol
- Talniflumate
- Phenyl salicylate
- Trolamine salicylate
- Menthyl salicylate
- Glycol salicylate
- Dipyrithione
- Bryostatin 1
- Alclofenac
- Bufexamac
- Bendazac
- Acemetacin
- Fish oil
- Medical Cannabis
- Nabiximols
|
- Esophageal cancer
- Penile cancer
- Cholangiocarcinoma
|
Novel |
PTPN1 |
protein tyrosine phosphatase non-receptor type 1 |
- Integrin signaling
- Negative regulation of MET activity
- Insulin receptor recycling
- Regulation of IFNG signaling
- PTK6 Down-Regulation
- MECP2 regulates neuronal receptors and channels
- Regulation of IFNA/IFNB signaling
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
- 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid
- 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
- [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
- {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
- Compound 19
- 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
- 2-(Oxalyl-Amino)-Benzoic Acid
- {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
- Novo Nordisk a/S Compound
- N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide
- 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- PNU177836
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
- (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
- 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
- L-cysteic acid
- 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
- -Carbonyl]-Amino}-Butyric Acid
- Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
- 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
- 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
- [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
- {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
- N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide
- 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
- ISIS 113715
- Trodusquemine
- Ertiprotafib
- 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
- [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
- 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
- 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
- [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
- 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
- 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
- 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
- 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
- N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
- [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
- 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
- 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
- ISOTHIAZOLIDINONE ANALOG
- 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
- p-Benzoyl-L-phenylalanine
- 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
- (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
- 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
- (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
|
|
Novel |
PTPN13 |
protein tyrosine phosphatase non-receptor type 13 |
- Synthesis of PIPs at the plasma membrane
- Interleukin-37 signaling
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
|
|
|
Novel |
PTPN14 |
protein tyrosine phosphatase non-receptor type 14 |
|
|
- Choanal atresia and lymphedema
|
Novel |
PTPN6 |
protein tyrosine phosphatase non-receptor type 6 |
- GPVI-mediated activation cascade
- Regulation of KIT signaling
- Signaling by ALK
- PECAM1 interactions
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- CD22 mediated BCR regulation
- Neutrophil degranulation
- Interferon gamma signaling
- Regulation of IFNG signaling
- Interleukin-37 signaling
- Interferon alpha/beta signaling
- Interleukin receptor SHC signaling
- Regulation of IFNA/IFNB signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Nuclear events stimulated by ALK signaling in cancer
- Growth hormone receptor signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Co-inhibition by BTLA
|
|
|
Novel |
PTPRB |
protein tyrosine phosphatase receptor type B |
|
- {4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID
- (4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID
- {4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID
- (4-ETHYLPHENYL)SULFAMIC ACID
- Razuprotafib
|
|
Novel |
PTPRF |
protein tyrosine phosphatase receptor type F |
- Receptor-type tyrosine-protein phosphatases
- Insulin receptor recycling
- Synaptic adhesion-like molecules
|
|
|
Novel |
PTPRJ |
protein tyrosine phosphatase receptor type J |
- Phosphorylation of CD3 and TCR zeta chains
- Neutrophil degranulation
- Negative regulation of MET activity
- Negative regulation of FLT3
|
|
|
Novel |
PTPRK |
protein tyrosine phosphatase receptor type K |
|
|
|
Novel |
PTPRM |
protein tyrosine phosphatase receptor type M |
|
|
|
Novel |
PTPRU |
protein tyrosine phosphatase receptor type U |
|
|
|
Novel |
PTPRZ1 |
protein tyrosine phosphatase receptor type Z1 |
- Other interleukin signaling
- MDK and PTN in ALK signaling
|
|
|